Dr. Burbidge is an experienced drug hunter with an in-depth expertise in both small molecule and biological drug discovery and development. In addition to his role at Rewind Therapeutics, he is currently Director of Discovery and Preclinical Projects at 3D Consultants, Cambridge (UK), an advisory company focusing on drug discovery and development. From 2009 to 2018, he held positions of increasing responsibility at Proximagen Ltd, Cambridge (UK), most recently as Head of Discovery and Preclinical Projects. During this period, he led multiple discovery and preclinical stage programs, successfully driving the selection of multiple clinical candidates. He was Project Leader for the VAP-1 inhibitor program, which as subsequently licensed to Roche following a successful Phase 2a clinical trial. He also led an Alpha-7 nicotinic program successfully in-licensed from GSK. From 1996 to 2008, he held roles of increasing responsibility at GlaxoWellcome and GlaxoSmithKline, leading, among others, external drug discovery programs. Dr. Burbidge started his career at GlaxoWellcome in early-stage drug discovery with a focus on neuroscience. He received his BSc in Biological Sciences and a PhD in Molecular Genetics from the University of Warwick (UK) and completed Post-Doctoral studies at the Ludwig Institute for Cancer Research, London (UK).